Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06104618 | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | recruiting | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06402357 | High Intensity Focused Ultrasound in Prostate Cancer | recruiting | Phase 2 | 25 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07626151 |
| Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy |
| recruiting |
| N/A |
| 90 |
| Nazmy Edward SeifOTHER |
| 1 |
| Jun 8, 2026 |
| clinicaltrials |
| NCT07631858 | Perspectives About Online Information | not yet recruiting | N/A | 3,200 | NYU Langone HealthOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632690 | QLC5508 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 3 | 700 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT00451022 | Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | recruiting | — | 750 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01802346 | Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer | active not recruiting | N/A | 130 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03650595 | MRI Guided Focal Laser Ablation of Prostate Cancer(MRgFLA) | recruiting | N/A | 102 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05168618 | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer(AtezoCab) | recruiting | Phase 2 | 33 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05304858 | Tumor Microenvironment Analysis of Prostate Cancer Metastasis | recruiting | — | 16 | Columbia UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05313815 | Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer(MOB-RT) | recruiting | N/A | 100 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06499870 | Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial | recruiting | Phase 2 | 50 | Sean SachdevOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06891664 | Feasibility of Day-surgery Management for Patients Undergoing Robotic Radical Prostatectomy: a Randomized Trial | active not recruiting | N/A | 90 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03445559 | A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging | active not recruiting | N/A | 58 | VA Office of Research and DevelopmentFED | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03725761 | Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | active not recruiting | Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03821246 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | recruiting | Phase 2 | 68 | David OhOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT06609005 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 84 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT03344211 | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05223803 | TERPS Trial for de Novo Oligometastic Prostate Cancer | recruiting | Phase 2 | 122 | University of Maryland, BaltimoreOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06003556 | PSMA-Guided Ablation of the Prostate(P-GAP) | recruiting | Phase 2 | 138 | University of AlbertaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06112990 | Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression(CREATINE-52) | recruiting | Phase 3 | 200 | University of UtahOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06500169 | Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors(GREENS) | recruiting | N/A | 20 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623460 | Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer(ZENITH) | not yet recruiting | Phase 2 | 30 | Stuthi PerimbetiOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07623941 | CUIMC Focal Therapy Registry | recruiting | — | 1,000 | Columbia UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05454488 | An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05470699 | RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer | active not recruiting | N/A | 34 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05477823 | Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05515978 | Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients(PragMet) | recruiting | Early Phase 1 | 100 | University of Colorado, DenverOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06228053 | Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer(SYNERGY-201) | recruiting | Phase 2 | 53 | Syntrix Biosystems, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06825091 | Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)(ASPIRE) | recruiting | Phase 3 | 320 | University Health Network, TorontoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07198633 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07620717 | Early Diagnosis of PROstate CANcer for Black Men(PROCAN-B+) | not yet recruiting | N/A | 300 | University of SunderlandOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07621692 | Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T | recruiting | Phase 1 | 12 | National Taiwan University HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03012321 | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | active not recruiting | Phase 2 | 70 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03600350 | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | active not recruiting | Phase 2 | 19 | University of Wisconsin, MadisonOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer(Rad2Nivo) | active not recruiting | Phase 1 | 39 | University of UtahOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05720910 | Streamlined Geriatric and Oncological Evaluation Based On IC Technology(FRONE) | active not recruiting | N/A | 720 | Institut BergoniéOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06474806 | Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer(uTRACE-101) | recruiting | Phase 2 | 168 | CurasightINDUSTRY | 3 | Jun 1, 2026 | clinicaltrials |
| NCT07145177 | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 30 | University of California, San FranciscoOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07344311 | A Phase I Trial of A-CAR032 in Participants With mCRPC | recruiting | Phase 1 | 27 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617272 | Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore(PARIS-BIO) | recruiting | Phase 2 | 100 | Region StockholmOTHER_GOV | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06822036 | EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER(ARISTA) | recruiting | N/A | 362 | St. Antonius Hospital GronauOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06964412 | The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy | active not recruiting | N/A | 36 | Brigham and Women's HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07393867 | Androgen-responsive POSLUMA-guided Intra-prostatic Boost(ARPEGGIO) | recruiting | Phase 2 | 23 | Martin T. King, MD, PhDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07567521 | A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC | recruiting | Phase 1 / Phase 2 | 90 | C Ray TherapeuticsINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07614256 | Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction | recruiting | — | 3,000 | Guangxi Medical UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 8, 2026source: clinicaltrials